Nontuberculous mycobacteria infection and tumor necrosis factor-alpha antagonists.
Reinout M
RM
Swart
Jakko
J
van Ingen
Dick
D
van Soolingen
Rob
R
Slingerland
Willem D H
WD
Hendriks
Jan G
JG
den Hollander
D000068879:Adalimumab; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D009164:Mycobacterium Infections / Q000382:microbiology*; D018393:Mycobacterium haemophilum / Q000302:isolation & purification*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D008727:Methotrexate